Differential control of 2-AG’s activity at CB1R by ABHD6 and MAGL
ABHD6 和 MAGL 对 CB1R 上 2-AG 活性的差异控制
基本信息
- 批准号:10664172
- 负责人:
- 金额:$ 19.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:2-arachidonylglycerolABHD6 geneAddressAdverse effectsAffectAgonistApplications GrantsBDKRB2 geneBiological ModelsBiosensorBradykininBrainCNR1 geneCannabinoidsCell LineCellsChronicCorpus striatum structureDevelopmentDrug AddictionElectrophysiology (science)EndocannabinoidsEnzymesFluorescence MicroscopyGoalsHydrolaseMAGL inhibitorMapsMeasuresMediatingMolecularMonoacylglycerol LipasesMusN-MethylaspartateNeuronsPresynaptic TerminalsProductionPropertyReceptor SignalingResearchRoleSignal TransductionSliceStimulusSynaptic TransmissionSystemTestingTherapeuticTimeTransfectionVeratridineWorkabuse liabilitycell typeendocannabinoid signalinglipoprotein lipasenervous system disordernovelnovel therapeuticspharmacologicpostsynapticpresynapticreceptorsensorside effectsmall moleculespatiotemporaltooltwo photon microscopy
项目摘要
Summary
The most abundant endocannabinoid (eCB) in brain, 2-arachidonoyl glycerol (2-AG), is inactivated by two
enzymes: monoacylglycerol lipase (MAGL) and α/β hydrolase domain-contain 6 (ABHD6) that differ in their
hydrolyzing activities and subcellular localization (presynaptic and postsynaptic, respectively). Accordingly,
selective inhibition of each enzyme results in different spatiotemporal enhancement of 2-AG-CB1R signaling in
the brain, and potentially synergistic therapeutic benefits.
We recently gathered results showing that stimulated increase in 2-AG production is reliably measured using
GRABeCB2.0, a recently developed 2-AG sensor. Remarkably, metabotropic receptor mediated increase in 2-AG
is controlled by ABHD6, whereas ionotropic receptor-dependent increase in 2-AG is not controlled by ABHD6.
These results raise the question of how MAGL controls stimulation-dependent 2-AG production?
Demonstrating that receptor-dependent increases in 2-AG production and activity at CB1R signaling are
differentially controlled by ABHD6 and MAGL would provide an additional level of mechanistic distinction
between these eCB-hydrolyzing enzymes. To increase our understanding of the respective roles of ABHD6 and
MAGL in controlling 2-AG-CB1R signaling in brain, we initiated an effort and have now successfully validated the
GRABeCB2.0 pharmacological profile in neural cells in culture and identified several stimuli that increase 2-AG
production. Based on this premise, we propose to address the following two questions in mouse neurons in
primary culture and striatal slices using live-cell fluorescence microscopy, two-photon microscopy and
electrophysiology:
Aim 1: Which stimuli increase 2-AG production and GRABeCB2.0 signal in neurons?
Aim 2: How do ABHD6 and MAGL differentially control stimuli-dependent increases in 2-AG-CB1R
signaling in neurons?
Completion of the work outlined in this new R21 grant proposal will provide a comprehensive understanding of
the respective role of ABHD6 and MAGL in controlling 2-AG-CB1R signaling in the brain. Our long-term goal is
to increase our understanding of the molecular, cellular, and system’s level differences by which ABHD6 and
MAGL control eCB signaling in brain, a body of work that will help develop novel therapeutics with reduced
potential for abuse and adverse effects produced by classic cannabinoid agonists.
摘要
大脑中含量最丰富的内源性大麻素(ECB)--2-花生四烯酸甘油(2-AG)被两种
酶:单甘油脂肪酶(MAGL)和α/β水解酶结构域-包含6个不同的
水解性和亚细胞定位(分别为突触前和突触后)。因此,
选择性抑制每种酶导致2-AG-CB1R信号的不同时空增强
大脑,以及潜在的协同治疗益处。
我们最近收集的结果表明,2-AG产量的刺激增加是通过使用
GRABeCB2.0,一种最近开发的2-AG传感器。值得注意的是,代谢性受体介导了2-AG的增加
是由ABHD6控制的,而2-AG的离子亲和性受体依赖性增加不受ABHD6控制。
这些结果提出了MAGL如何控制依赖刺激的2-AG生产的问题?
证明受体依赖的2-AG的产生和CB1R信号活性的增加是
由ABHD6和MAGL控制的差异化将提供额外的机械区分级别
在这些欧洲央行水解酶之间。为了加深我们对ABHD6和ABHD6各自作用的理解
MAGL在控制大脑中的2-AG-CB1R信号转导方面,我们发起了一项努力,现在已经成功地验证了
GRABeCB2.0在培养神经细胞中的药理学特征及几种可增加2-AG的刺激物
制作。基于这一前提,我们提出了以下两个关于小鼠神经元的问题
原代培养和纹状体切片使用活细胞荧光显微镜,双光子显微镜和
电生理学:
目的1:哪些刺激能增加神经元中2-AG的产生和GRABeCB2.0信号?
目的2:ABHD6和MAGL如何不同地控制2-AG-CB1R中刺激依赖性的增加
神经元中的信号?
完成这项新的R21拨款提案中概述的工作将提供对
ABHD6和MAGL分别在脑内控制2-AG-CB1R信号转导中的作用。我们的长期目标是
为了增加我们对ABHD6和ABHD6和ABHD6在分子、细胞和系统水平上的差异的理解
MAGL控制大脑中的ECB信号,这是一项有助于开发新疗法的工作,减少了
经典大麻素激动剂可能产生的滥用和不良影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nephi Stella其他文献
Nephi Stella的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nephi Stella', 18)}}的其他基金
Role of CB1R expressed in the prefrontal cortex in the control of locomotion
前额皮质表达的 CB1R 在运动控制中的作用
- 批准号:
10590320 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Differential response of glioblastomas to microtubule targeting agents
胶质母细胞瘤对微管靶向剂的差异反应
- 批准号:
10208829 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Differential response of glioblastomas to microtubule targeting agents
胶质母细胞瘤对微管靶向剂的差异反应
- 批准号:
10650168 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Impact on adult mouse brain of oral THC and CBD consumption during adolescence
青春期口服 THC 和 CBD 对成年小鼠大脑的影响
- 批准号:
10206087 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Molecular mechanism of ABHD6 enzymatic activity in neurons
神经元ABHD6酶活性的分子机制
- 批准号:
10040363 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Differential response of glioblastomas to microtubule targeting agents
胶质母细胞瘤对微管靶向剂的差异反应
- 批准号:
10434745 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Impact on adult mouse brain of oral THC and CBD consumption during adolescence
青春期口服 THC 和 CBD 对成年小鼠大脑的影响
- 批准号:
10039866 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Novel microtubule-targeting agents for the treatment of glioblastoma multiform
用于治疗多形性胶质母细胞瘤的新型微管靶向药物
- 批准号:
9755531 - 财政年份:2018
- 资助金额:
$ 19.44万 - 项目类别:
Anti-Epileptic Action of ABHD6 Inhibitors as Treatment for Dravet Syndrome
ABHD6 抑制剂治疗 Dravet 综合征的抗癫痫作用
- 批准号:
9331065 - 财政年份:2017
- 资助金额:
$ 19.44万 - 项目类别:














{{item.name}}会员




